InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Smith W Bradford, Chief Financial Officer. Officer active across 2 companies, notably Homology Medicines, Inc.. Aggregated, 4 filings have been recorded. Split: 0 buy · 1 sell. Total volume traded: €5k. History available since 9 January 2023. The latest transaction was disclosed on 14 May 2026 (Disposition). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Smith W Bradford
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
640 shares0Common StockSEC:0001193125-26-227500:0
3,729 shares@ US$1.3912100.0% of flowCommon StockSEC:0000899243-23-001576:0
6,600 sharesCommon StockSEC:0000899243-23-000626:0
6,600 sharesCommon StockSEC:0000899243-22-001749:0
4 of 4 declarations
About Smith W Bradford
W. Bradford Smith is the CFO & Treasurer at Homology Medicines, Inc. and Lyra Therapeutics, Inc. He oversees the financial operations of both companies, including budgeting and financial reporting. With significant experience in finance, Smith plays a key role in managing financial resources and growth strategy.
